Biotech News

NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy

NuCana plc (NCNA)NuCana plc2025-10-14 12:00 ESTCompany update

NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows Patient with Melanoma Remains Progression-Free at 23 Months with a Durable Partial Response Preclinical Data Corroborate Immunogenic Effects of NUC-3373

Related news

NCNANuCana plc2026-08-13 20:01 EST

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

KURAKura Oncology2026-06-11 12:02 EST

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

BMYBMYBristol-Myers Squibb Company2026-08-13 21:12 EST

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

REPLReplimune Group2026-08-06 20:00 EST

Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen

TEVATeva Pharmaceutical Industries2026-07-07 11:00 EST

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

BNTXBioNTech2026-08-20 09:30 EST

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

RVMDRevolution Medicines2026-07-02 12:00 EST

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

CHRSCoherus BioSciences, Inc.2026-06-23 18:00 EST

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

NRIXNurix Therapeutics2026-06-11 11:00 EST

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

View all latest news

NuCana plc

ProTide Oncology Company NuCana applies its ProTide chemistry platform to transform nucleoside analogs into medicines designed to generate higher concentrations of active anticancer metabolites inside tumor cells. NUC-7738 NUC-7738 is a ProTide that disrupts RNA polyadenylation and affects multiple components of the tumor...

Recent company news

NCNANuCana plc2026-08-13 20:01 EST

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

NCNANuCana plc2026-06-01 12:00 EST

NuCana Appoints Ian Webster as Chief Financial Officer

NCNANuCana plc2026-05-14 20:01 EST

NuCana Reports First Quarter 2026 Financial Results and Provides Business Update

NCNANuCana plc2026-03-19 20:01 EST

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NCNANuCana plc2026-01-06 13:00 EST

NuCana Appoints Theresa Bruce as Chief Operating Officer

Stock data

Close: 1.52 USD
Market cap: 8.62M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States